Related Experiment Video
Updated: May 9, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
D Leopardo1, S C Cecere, M Di Napoli
1Uro-Gynecologic Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale", IRCCS, Napoli, Italia. s.pignata@istitutotumori.na.it.
European Review for Medical and Pharmacological Sciences
|July 30, 2013
Summary
Non-muscle-invasive bladder cancer (NMIBC) often recurs after surgery. Risk stratification guides adjuvant chemo-immunotherapy, with varying treatment durations for low, intermediate, and high-risk patients to prevent recurrence and progression.
Area of Science:
- Urology
- Oncology
- Cancer Research
Background:
- Non-muscle-invasive bladder cancer (NMIBC) constitutes 75-85% of new bladder cancer diagnoses annually.
- Transurethral resection is the primary diagnostic and therapeutic intervention for NMIBC.
- Disease recurrence and progression are significant concerns following initial treatment, influenced by factors like tumor multiplicity, T dimension, and prior recurrence history.
Purpose of the Study:
- To review current data on adjuvant chemo-immunotherapy for NMIBC.
- To discuss the role of different drugs in managing NMIBC based on risk stratification.
- To highlight treatment strategies for preventing recurrence and progression in NMIBC patients.
Main Methods:
- Review of existing literature and clinical data on NMIBC treatment.
- Analysis of risk factors influencing recurrence and progression.
- Evaluation of adjuvant chemo-immunotherapy regimens based on patient risk categories.
Main Results:
- Standard treatment for low-risk NMIBC involves a single chemotherapy instillation without maintenance.
- Intermediate-risk patients benefit from induction and maintenance therapy (chemotherapy or immunotherapy) for at least one year.
- High-risk patients are recommended adjuvant induction and maintenance immunotherapy for up to three years.
Conclusions:
- Risk stratification is crucial for tailoring adjuvant therapy in NMIBC.
- Adjuvant chemo-immunotherapy plays a vital role in reducing recurrence and progression rates.
- The choice and duration of therapy depend on individual patient risk factors and disease characteristics.
